Drug intelligence / Profile preview

CD19 and CD22 targeted CAR-T cells

Development stage: Phase 2
Lead developer: Chongqing Precision Biotech Co., Ltd
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

CD19 and CD22 targeted CAR-T cells represent a novel cell therapy approach utilizing chimeric antigen receptor (CAR) T-cells engineered to recognize and eliminate malignant B-cells expressing both CD19 and CD22 antigens. This dual-targeting strategy aims to enhance therapeutic efficacy and overcome potential antigen escape mechanisms in patients with relapsed/refractory B-cell leukemia and lymphoma. The therapy involves a single intravenous infusion of these modified T-cells. It is currently being developed by Chongqing Precision Biotech Co., Ltd.

Other names: CD19/CD22 dual targeted CAR-T cellsCD19/CD22 bicistronic CAR-T cellsCD19 and CD22 cotransduced CAR-T cellsCD-19 and CD22 cotransduced CAR-T cellsCD 19 and CD22 cotransduced CAR-T cells

Targets

CD19 (B lymphocyte antigen CD19)CD22 (Cluster of Differentiation 22)

Beyond the preview

Go deeper on CD19 and CD22 targeted CAR-T cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD19 and CD22 targeted CAR-T cells.

Explore the full profile